Daraxonrasib, also known by its development code RMC-6236, is a pan-RAS inhibitor developed by Revolution Medicines. It is designed to target multiple oncogenic RAS variants (KRAS, NRAS, HRAS) through a RAS(ON) multi-selective inhibition mechanism, and is currently under clinical investigation for RAS-mutant solid tumors.
As a dedicated supplier of pharmaceutical intermediates and APIs,
EOS Med CDMO offers Daraxonrasib for research and development use, We support scale-up production up to kilogram levels and provide full Drug Master File (DMF) documentation support. Every shipment comes with complete technical dossiers, including COA, MSDS, and analytical data (HPLC/HNMR), to ensure seamless regulatory compliance for your project.
Supply Capability
stock: In stock
Batch size: 500 kg
Purity: 98%+ (HPLC)
Production: GMP-compliant facility
Documentation (available on request)
COA (Certificate of Analysis)
HNMR spectrum
MSDS / SDS
DMF support available
Specifications
CAS Number: 2765081-21-6
Synonyms: RMC-6236, RAS-IN-2
Molecular Formula: C44H58N8O5S
Molecular Weight: 803.06
Target: pan-RAS (RAS-ON inhibitor)
Research Area: Oncology / RAS-mutant cancers
Transportation Conditions: This product is a non-hazardous chemical and should be transported at room temperature. It can be stably stored for several weeks during normal transportation and customs clearance.
Storage Conditions: Short-term (days to weeks) storage at 0-4°C; long-term (months to years) storage at -20°C.
Solubility: To be determined.
Shelf Life: Over 2 years under proper storage conditions.
Pharmaceutical Preparations: To be determined.
Catalyst Storage: Short-term (days to weeks) storage at 0-4°C; long-term (months) storage at -20°C.
HS Code: 2934.99.9001
For pricing, current stock, or to request a sample of Daraxonrasib
(CAS 2765081-21-6), please submit an inquiry below.